Download PDF
Pneumologie 2002; 56(12): 773-780
DOI: 10.1055/s-2002-36128
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

Bedeutung der pulmonalen Lymphknotenmetastasierung bei lokal fortgeschrittenen, nicht-kleinzelligen Bronchialkarzinomen

Significance of Pulmonary Lymph Node Metastases in Locally Advanced Non-Small Cell Lung CancerA.  Marra1 , L.  Hillejan1 , C.  Pöttgen2 , G.  Zaboura1 , S.  Fechner1 , D.  Greschuchna1 , G.  Stamatis1
  • 1Abteilung für Thoraxchirurgie und thorakale Endoskopie (Chefarzt: PD Dr. med. G. Stamatis), Ruhrlandklinik, Essen
  • 2Strahlenklinik, Westdeutsches Tumorzentrum, Universitätsklinikum Essen (Chefarzt Prof. Dr. med. M. Stuschke), Essen
Diese Studie wurde der Ruhrlandklinik zu ihrem 100-jährigen Jubiläum gewidmet.DanksagungDie Autoren bedanken sich bei Frau Barbara Daut für ihre wertvolle Mitarbeit in der Sammlung und Bearbeitung der Patientendaten.
Further Information

Publication History

Publication Date:
12 December 2002 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Hintergrund: Das lokal fortgeschrittene (T3 - 4) nicht-kleinzellige Bronchialkarzinom mit pulmonalen Lymphknotenmetastasen (N1) beinhaltet unterschiedliche Tumormanifestationen, die verschiedenen lymphatischen Metastasierungsmustern und möglicherweise Prognosen entsprechen. Patienten und Methode: Retrospektiv wurden die Krankenblätter und Verlaufsunterlagen der 181 Patienten mit pathologischem Tumorstadium IIIA-pT3N1 und IIIB-pT4N1 erfasst, die im Zeitraum 1990 - 1995 operiert wurden. Der Altersmedian betrug 62 Jahre (Bereich: 34 - 80 Jahre). Ergebnisse: Nach 188 resektiven Eingriffen betrug die 30-Tage-Letalität 3,7 %. Die folgende Analyse betrifft die 181 überlebenden Patienten, wobei 110 (60,8 %) Pneumonektomien und 71 (39,2 %) Lobektomien/Bilobektomien durchgeführt wurden. Das pathologische Stadium nach der UICC-Klassifikation 1997 lautete T3N1 in 128 (70,7 %) und T4N1 in 53 (29,3 %). Ein metastatischer Befall der hilären, interlobären und lobären Lymphknoten wurde in 44 (24,3 %), 17 (9,4 %) bzw. 27 (14,9 %) Patienten nachgewiesen, eine direkte Lymphknoteninfiltration in 93 Patienten (51,4 %). Die 3-, 5- und 10-Jahres-Überlebensraten nach Kaplan-Meier betrugen für N1 hilär 23 %, 13 % und 8 %, für N1 interlobär 18 %, 6 % und 0 %, für N1 lobär 48 %, 37 % und 22 %, und für N1 direkt 32 %, 27 % und 21 %. Der Befall der hilären Lymphknoten korrelierte mit einer eindeutig ungünstigeren Prognose (p = .0366). Schlussfolgerungen: Die metastatische Absiedlung in hiläre Lymphknoten bei lokal fortgeschrittenem NSCLC kann prognostisch als initiale N2-Erkrankung betrachtet werden und erfordert eine entsprechende Behandlung. Die direkte Infiltration der pulmonalen Lymphknoten erscheint prognostisch weniger ungünstig für die betroffenen Patienten.

Abstract

Background. The locally advanced (T3 - 4) non-small cell lung cancer with pulmonary lymph node metastases (N1) is a mixture of different subgroups of disease with varying pattern of tumor extension and long-term survival rates. Patients and methods: We retrospectively reviewed hospital records and follow-up data of 181 patients operated on between 1990 and 1995 with pathological stage IIIA-pT3N1 and IIIB-pT4N1. Median age was 62 years (range 34 - 80). Results: The operative mortality was 3.7 %. The analysis was carried out on the 181 hospital survivors. The operative procedure was a pneumonectomy in 110 cases (60.8 %) and a lobectomy/bilobectomy in 71 (39.26 %). The pathological stage according to the UICC TNM-Classification of 1997 was T3N1 in 128 (70.7 %) and T4N1 in 53 (29.3 %). We observed a metastatic involvement of the hilar, interlobar and lobar lymph nodes in 44 (24.3 %), 17 (9.4 %), and 27 (14.9 %) patients, respectively, whereas a direct infiltration in 93 patients (51.4 %). The actuarial overall 3-, 5- and 10-year survival rates for N1 hilar was 23 %, 13 % and 8 %, for N1 interlobar was 18 %, 6 % and 0 %, for N1 lobar was 48 %, 37 % and 22 %, and for N1 direct was 32 %, 27 % and 21 %, respectively. The involvement of hilar lymph nodes correlates with a worse prognosis (p = .0366). Conclusions: Metastases to the hilar lymph nodes in locally advanced NSCLC can be considered an initial N2-disease and should be treated correspondingly. Lymph node involvement by direct invasion is associated with a relatively more favourable prognosis for the patients.

Literatur

  • 1 PORT Meta-analysis Trialists Group . Postoperative radiotherapy in non-small cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomized controlled trials.  Lancet. 1998;  352 257-263
    CrossrefPubMedGoogle Scholar
  • 2 Mountain C F. Revisions in the International System for staging lung cancer.  Chest. 1997;  111 1710-1717
    CrossrefPubMedGoogle Scholar
  • 3 Fujimoto T, Zaboura G, Fechner S. et al . Completion pneumonectomy: Current indications, complications, and results.  J Thorac Cardiovasc Surg. 2001;  121 484-490
    CrossrefPubMedGoogle Scholar
  • 4 World Health Organization .International histological classification of tumours. Geneva: World Health Organization 1969 - 1981; 2nd ed. Berlin: Springer-Verlag 1988-Present
    Google Scholar
  • 5 Mountain C F, Dresler C M. Regional lymph node classification for lung cancer staging.  Chest. 1997;  111 1718-1723
    CrossrefPubMedGoogle Scholar
  • 6 Kaplan E L, Meier P. Nonparametric estimation from incomplete observations.  J Am Stat Assoc. 1958;  53 457-481
    CrossrefPubMedGoogle Scholar
  • 7 Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration.  Cancer Chemother Rep. 1966;  50 163-170
    PubMedGoogle Scholar
  • 8 Cox D R. Regression models and life tables.  J R Stat Soc B. 1972;  34 187-220
    PubMedGoogle Scholar
  • 9 Yano T, Yokoyama H, Inoue T. et al . Surgical results and prognostic factors of pathologic N1 disease in non-small-cell carcinoma of the lung. Significance of N1 level: lobar or hilar nodes.  J Thorac Cardiovasc Surg. 1994;  107 1398-1402
    PubMedGoogle Scholar
  • 10 van Velzen E, Snijder R J, Brutel de la Riviere A. et al . Type of lymph node involvement influences survival rates in T1N1M0 non-small cell lung carcinoma. Lymph node involvement by direct extension compared with lobar and hilar node metastases.  Chest. 1996;  110 1469-1473
    PubMedGoogle Scholar
  • 11 van Velzen E, Snijder R J, Brutel de la Riviere A. et al . Lymph node type as a prognostic factor for survival in T2 N1 M0 non-small cell lung carcinoma.  Ann Thorac Surg. 1997;  63 1436-1440
    CrossrefPubMedGoogle Scholar
  • 12 van Velzen E, Brutel de la Riviere A, Elbers H J. et al . Type of lymph node involvement and survival in pathologic N1 stage III non-small cell lung carcinoma.  Ann Thorac Surg. 1999;  67 903-907
    CrossrefPubMedGoogle Scholar
  • 13 Asamura H, Suzuki K, Kondo H. et al . Where is the boundary between N1 and N2 stations in lung cancer?.  Ann Thorac Surg. 2000;  70 1839-1845 discussion. 1845-1846
    CrossrefPubMedGoogle Scholar
  • 14 Maggi G, Casadio C, Mancuso M. et al . Resection and radical lymphadenectomy for lung cancer: prognostic significance of lymphatic metastases.  Int Surg. 1990;  75 17-21
    PubMedGoogle Scholar
  • 15 Martini N, Burt M E, Bains M S. et al . Survival after resection of stage II non-small cell lung cancer.  Ann Thorac Surg. 1992;  54 460-465 discussion. 466
    PubMedGoogle Scholar
  • 16 Riquet M, Manac'h D, Le Pimpec-Barthes F. et al . Prognostic significance of surgical-pathologic N1 disease in non-small cell carcinoma of the lung.  Ann Thorac Surg. 1999;  67 1572-1576
    CrossrefPubMedGoogle Scholar
  • 17 Yoshino I, Nakanishi R, Osaki T. et al . Unfavorable prognosis of patients with stage II non-small cell lung cancer associated with macroscopic nodal metastases.  Chest. 1999;  116 144-149
    CrossrefPubMedGoogle Scholar
  • 18 Naruke T, Goya T, Tsuchiya R. et al . Prognosis and survival in resected lung carcinoma based on the new international staging system.  J Thorac Cardiovasc Surg. 1988;  96 440-447
    PubMedGoogle Scholar
  • 19 Marra A, Hillejan L, Zaboura G. et al .Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis. J Thorac Cardiovasc Surg 2002 [in press]
    Google Scholar
  • 20 Ferguson M K, Little A G, Golomb H M. et al . The role of adjuvant therapy after resection of T1 N1 M0 and T2 N1 M0 non-small cell lung cancer.  J Thorac Cardiovasc Surg. 1986;  91 344-349
    PubMedGoogle Scholar
  • 21 Marks L B, Prosnitz L R. Postoperative radiotherapy for lung cancer: the breast cancer story all over again?.  Int J Radiat Oncol Biol Phys. 2000;  48 625-627
    CrossrefPubMedGoogle Scholar
  • 22 Sawyer T E, Bonner J A, Gould P M. et al . Factors predicting patterns of recurrence after resection of N1 non-small cell lung carcinoma.  Ann Thorac Surg. 1999;  68 1171-1176
    CrossrefPubMedGoogle Scholar
  • 23 Wagner H. Postoperative adjuvant therapy for patients with resected non-small cell lung cancer: still controversial after all these years.  Chest. 2000;  117 110S-118S
    CrossrefPubMedGoogle Scholar
  • 24 Bunn P A, Mault J, Kelly K. Adjuvant and neoadjuvant chemotherapy for non-small cell lung cancer. A time for reassessment?.  Chest. 2000;  117 119S-122S
    CrossrefPubMedGoogle Scholar
  • 25 Strauss G M. Role of chemotherapy in stages I to III non-small cell lung cancer.  Chest. 1999;  116 509S-516S
    CrossrefPubMedGoogle Scholar
  • 26 Non-small Cell Lung Cancer Collaborative Group . Chemotherapy in non-small cell lung cancer: meta-analysis using updated data on individual patients from 52 randomized clinical trials.  BMJ. 1995;  311 899-909
    Google Scholar
  • 27 Rosell R, Gomez-Codina J, Camps C. et al . A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.  N Engl J Med. 1994;  330 153-158
    CrossrefPubMedGoogle Scholar
  • 28 Roth J A, Fossella F, Komaki R. et al . A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.  J Natl Cancer Inst. 1994;  86 673-680
    CrossrefPubMedGoogle Scholar
  • 29 Eberhardt W, Wilke H, Stamatis G. et al . Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small cell lung cancer: mature results of a phase II trial.  J Clin Oncol. 1998;  16 622-634
    PubMedGoogle Scholar
  • 30 Stamatis G, Eberhardt W, Stüben G. et al . Preoperative chemoradiotherapy and surgery for selected non-small cell lung cancer IIIB subgroups: long-term results.  Ann Thorac Surg. 1999;  68 1144-1149
    CrossrefPubMedGoogle Scholar
  • 31 Pisters K M, Ginsberg R J, Giroux D J. et al . Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team.  J Thorac Cardiovasc Surg. 2000;  119 429-439
    CrossrefPubMedGoogle Scholar

Dr. med. A. Marra

Abteilung für Thoraxchirurgie und thorakale Endoskopie, Ruhrlandklinik

Tüschener Weg 40

45239 Essen